192701-73-8

Basic information

• Product Name: METHYL 3-P-TOLYL-1H-PYRAZOLE-5-CARBOXYLATE
• Synonyms: METHYL 3-P-TOLYL-1H-PYRAZOLE-5-CARBOXYLATE;Methyl 5-(p-tolyl)-1H-pyrazole-3-carboxylate;methyl 3-(4-methylphenyl)-1H-pyrazole-5-carboxylate;-1H-pyrazole-5-carboxylate;Methyl 3-(p-tolyl)
• CAS NO: 192701-73-8
• Molecular Formula: C₁₂H₁₂N₂O₂
• Molecular Weight: 216.239
• Mol File: 192701-73-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: METHYL 3-P-TOLYL-1H-PYRAZOLE-5-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-P-TOLYL-1H-PYRAZOLE-5-CARBOXYLATE(192701-73-8)
• EPA Substance Registry System: METHYL 3-P-TOLYL-1H-PYRAZOLE-5-CARBOXYLATE(192701-73-8)

Safety Data

• Hazardous Substances Data: 192701-73-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 3-P-TOLYL-1H-PYRAZOLE-5-CARBOXYLATE is used as a building block for the development of various beneficial drugs. Its unique attributes as a derivative of pyrazole make it a promising candidate for creating new pharmaceutical compounds.
Used in Biochemical Research:
METHYL 3-P-TOLYL-1H-PYRAZOLE-5-CARBOXYLATE is used as a research tool in biochemistry, particularly in the study of pharmacological processes. Its role as a potential pharmacophore allows researchers to explore its interactions with biological targets and understand its potential applications in drug discovery.
Used as a Biological Process Inhibitor:
METHYL 3-P-TOLYL-1H-PYRAZOLE-5-CARBOXYLATE is used as an inhibitor for certain biological processes. Its ability to interfere with specific pathways or mechanisms can be harnessed to develop targeted therapies or to study the underlying biology of certain conditions.

Upstream product

• 67-56-1 methanol 
• 46413-67-6 5-(4-methylphenyl)-1H-pyrazole-3-carboxylic acid 
• 39757-29-4 methyl 2,4-dioxo-4-p-tolylbutanoate 
• 1589523-24-9 methyl (E)-2-diazo-4-(p-tolyl)but-3-enoate 
• 127404-74-4 (E)-4-(4-tolyl)-3-butenoic acid 
• 1250907-64-2 methyl (E)-4-(p-tolyl)but-3-enoate 
• 51114-94-4 (2-carboxyethyl)triphenylphosphonium bromide 
• 122-00-9 para-methylacetophenone 

Downstream Products

• 1029087-20-4 methyl 1-(tetrahydro-2H-pyran-2-yl)-5-p-tolyl-1H-pyrazole-3-carboxylate 
• 46413-67-6 5-(4-methylphenyl)-1H-pyrazole-3-carboxylic acid 
• 1416981-55-9 C₃₃H₃₁N₃O₈ 
• 1375158-52-3 methyl 1-benzyl-3-(4-methylphenyl)-1H-pyrazole-5-carboxylate 
• 1375158-53-4 methyl 1-benzyl-5-(4-methylphenyl)-1H-pyrazole-3-carboxylate 
• 1375158-57-8 1-benzyl-3-(4-methylphenyl)-N-(pyridin-3-ylmethyl)-1H-pyrazole-5-carboxamide 
• 1375158-58-9 1-benzyl-3-(4-methylphenyl)-N'-quinolin-2-yl-1H-pyrazole-5-carbohydrazide 
• 1375158-59-0 4-tert-butylphenyl 1-benzyl-3-(4-methylphenyl)-1H-pyrazole-5-carboxylate 
• 1375158-60-3 4-(isopropyl)phenyl 1-benzyl-3-(4-methylphenyl)-1H-pyrazole-5-carboxylate 
• 1375158-61-4 4-(heptyloxy)phenyl 1-benzyl-3-(4-methylphenyl)-1H-pyrazole-5-carboxylate 
• 1375158-62-5 4-[4-(trifluoromethyl)phenoxy]phenyl 1-benzyl-3-(4-methylphenyl)-1H-pyrazole-5-carboxylate 
• 1375158-63-6 4-(1H-imidazol-1-yl)phenyl 1-benzyl-3-(4-methylphenyl)-1H-pyrazole-5-carboxylate 
• 1375158-64-7 ethyl 1-{[1-benzyl-5-(4-methylphenyl)-1H-pyrazol-3-yl]carbonyl}piperidine-4-carboxylate 
• 1375158-65-8 1-{[1-benzyl-5-(4-methylphenyl)-1H-pyrazol-3-yl]carbonyl}-4-(4-tert-butylbenzyl)piperazine 

Relevant articles and documents

Intramolecular Cyclization of Vinyldiazoacetates as a Versatile Route to Substituted Pyrazoles

Vinyldiazo compounds undergo a thermal electrocyclization to form pyrazoles in yields of up to 95percent. The reactions are operationally simple, use readily available starting materials, require no intervention of a catalyst, and enable the synthesis of mono-, di- A nd tri-substituted pyrazoles. With the ability to produce highly substituted pyrazoles and the flexibility in installing various types of substituents, this method constitutes a new entry to this valuable heterocyclic scaffold and may be of interest to all branches of the chemical industry.

Synthesis and anticancer activity of heteroaromatic linked 4β-amido podophyllotoxins as apoptotic inducing agents

A series of different heteroaromatic linked 4β-amidopodophyllotoxin conjugates (16a-i, 17a-i and 18a-d) were synthesized and evaluated for anticancer activity against five human cancer cell lines. Among the series, one of the compound 17g showed significant antiproliferative activity in A549 (lung cancer) cell line. Flow cytometric analysis showed that 17g arrested the cell cycle in the G2/M phase leading to caspase-3 dependent apoptotic cell death. Further, Hoechst 33258 staining and DNA fragmentation assay also suggests that 17g induces cell death by apoptosis.

Synthesis and evaluation of analgesic, anti-inflammatory, and anticancer activities of new pyrazole-3(5)-carboxylic acid derivatives

In this article, we synthesized a series of novel 1-benzyl-5(3)-p-tolyl-1H- pyrazole-3(5)-carboxylic acid derivatives and characterized by IR, 1H NMR, and mass spectroscopy. Compounds were evaluated for their in vivo analgesic and anti-inflammatory activity using the p-benzoquinone-induced writhing test and the carrageenan-induced paw edema model, respectively. Out of 14 compounds tested, 7a, 7c, 7e, 7f, 7i, 8a-b, and 8f-g exhibited potent analgesic and/or anti-inflammatory activity as compared to reference drugs aspirin and indomethacin. Anticancer activity of these compounds was assessed against five cancer cell lines with the MTT assay (HL-60, human promyelocytic leukemia cells; HeLa, human cervical cancer cells; Raji, human B lymphocyte cell line; MCF7, human breast adenocarcinoma cell line; MDA-MB-231, estrogen-independent human breast cancer cell line). Compounds 7a, 8a, and 8b with high anti-inflammatory activity, and also 7d and 7j with mild anti-inflammatory activity exhibited promising anticancer activity against some selected cell lines.

NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS

The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.